A Phase 2 interventional study of TQH2722 injection in Seasonal Allergic Rhinitis, sponsored by Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.. Recruiting at 30 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-27.
Sponsored by Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Rhinitis, Allergic, Seasonal with a site in China — 12 open to participants now, 14 under way, 8 of them phase 3. Rhinitis, Allergic, Seasonal · China.
Among the 27 studies in Rhinitis, Allergic, Seasonal with a site in China, this one is the 8th largest by planned enrollment, is one of 6 that started in 2026, is one of 12 in phase 2, reaches primary completion later than 9 of the 13 other live ones, and was the 22nd registered.
404 studies on the registry are indexed under Rhinitis, Allergic, Seasonal; 24 are open to participants now.
Browse Rhinitis, Allergic, Seasonal studies →12 of the 27 studies in Rhinitis, Allergic, Seasonal with a site in China are open now. Recruiting first, the newest first:
Fujian Mindong Rejuvenation Pharmaceutical Co., Ltd. · Sites in China
Ages 18–65
Chengdu Kangnuoxing Biopharma,Inc. · Sites in China
Ages 12–18
Genrix (Shanghai) Biopharmaceutical Co., Ltd. · Sites in China
Ages 18–75
Shanghai Mabgeek Biotech.Co.Ltd · Sites in China
Ages 18–75
Beijing Tongren Hospital · Sites in China
Ages 18–65
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 17 Rhinitis, Allergic, Seasonal studies recruiting now, 2 (12%) set no upper age limit and 15 (88%) stop at 75 or younger; 1 takes children under 18; 5 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 13 · Phase 3 11
First in 2017; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 131 across 366 interventional studies indexed under Rhinitis, Allergic, Seasonal.
Median enrollment 160 across the 27 interventional studies. Of the 12 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 27 have an industry lead sponsor. The 10 most frequent:
This study is registered under Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd., one of the names counted as Sino Biopharmaceutical Limited. Under that name alone:
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. is the lead sponsor of 18 studies on the registry; 14 are open to participants now.
Sino Biopharmaceutical Limited has 3 studies filed under Rhinitis, Allergic, Seasonal — fewer than ten, so there is no comparison to draw.
5 of the studies in Rhinitis, Allergic, Seasonal with a site in China that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07688772Phase 3Guangdong Hengrui Pharmaceutical Co., LtdA Clinical Study Evaluating the Efficacy and Safety of SHR-1819 Injection in Patients With Seasonal Allergic Rhinitis | 2026-12 |
| NCT07678931Phase 3Chengdu Kangnuoxing Biopharma,Inc.Study on the Treatment of Adolescent Patients With Seasonal Allergic Rhinitis | 2026-12 |
| NCT07199257Phase 3Genrix (Shanghai) Biopharmaceutical Co., Ltd.A Study of GR1802 Injection in Patients With Seasonal Allergic Rhinitis. | 2027-05-15 |
| NCT07711262Phase 3Fujian Mindong Rejuvenation Pharmaceutical Co., Ltd.Rupatifen Fumarate Capsules in Patients With Seasonal Allergic Rhinitis | 2027-10 |
| NCT07398859Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.Clinical Study on TQH2722 Injection Combined With Background Therapy for Seasonal Allergic Rhinitis | 2026-11 |
Add all 5 to your calendar (.ics) → With an account.
Among the 27 studies in Rhinitis, Allergic, Seasonal with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a multicenter, open-label, Phase II, single-arm clinical trial, with a planned enrollment of 200 to 300 subjects. Its primary objective is to evaluate the safety and efficacy of TQH2722 injection in the treatment of seasonal allergic rhinitis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Injection combined with TQH2722, 2 weeks as a treatment cycle.
Drug: TQH2722 injection
TQH2722 injection is a humanized monoclonal antibody targeting interleukin-4 receptor alpha (IL-4Rα).
Number of subjects with incidence of adverse event
Adverse events occurring during treatment.
Time frame: Baseline up to 4 weeks
Number of subjects with incidence of serious adverse event
Serious adverse event occurring during treatment.
Time frame: Baseline up to 4 weeks
Number of subjects with incidence of abnormality check indicators
Number of subjects with incidence of abnormality check indicators: Abnormal examination indicators occurred during treatment.
Time frame: Baseline up to 4 weeks
Retrospective nasal symptom score after treatment for 2 weeks
The average change in the retrospective total nasal symptom score (rTNSS) per day over 2 weeks of treatment compared to baseline. The total score is 0-12 points, with the higher score meaning the more severe symptoms.
Time frame: Baseline up to 2 weeks
Retrospective nasal symptom score after treatment for 4 weeks
The average change in the retrospective total nasal symptom score (rTNSS) per day over 4 weeks of treatment compared to baseline. The total score is 0-12 points, with the higher score meaning the more severe symptoms.
Time frame: Baseline up to 4 weeks
Mean daily morning retrospective total nasal symptom score
Mean change from baseline in the morning retrospective total nasal symptom score (AM rTNSS) at 2 weeks and 4 weeks of treatment. The total score is 0-12 points, with the higher score meaning the more severe symptoms.
Time frame: Baseline up to 2 and 4 weeks
Mean daily retrospective total nasal symptom score at night
Mean change from baseline in the Post-Medication Reviewed Total Nasal Symptom Score (PMrTNSS) at night per day at 2 weeks and 4 weeks of treatment. The total score is 0-12 points, with the higher score meaning the more severe symptoms.
Time frame: Baseline up to 2 and 4 weeks
Total instantaneous nasal symptom score before medication in the morning every day
Mean change from baseline in instantaneous total nasal symptom score (iTNSS) before medication administration in the morning, for each day during the 2-week and 4-week treatment periods. The total score is 0-12 points, with the higher score meaning the more severe symptoms.
Time frame: Baseline up to 2 and 4 weeks
Daily retrospective total nasal symptom score
Mean percentage change from baseline in daily rTNSS at 2 weeks and 4 weeks of treatment.
Time frame: Baseline up to 2 and 4 weeks
Total instantaneous nasal symptom score before medication in the morning every day
Mean percentage change from baseline in iTNSS before medication administration in the morning, for each day during the 2-week and 4-week treatment periods.
Time frame: Baseline up to 2 and 4 weeks
Daily retrospective scoring of individual nasal symptoms
Mean change from baseline in daily retrospective nasal single symptom scores at 2 weeks and 4 weeks of treatment.
Time frame: Baseline up to 2 and 4 weeks
Daily retrospective nasal single symptom score during daytime
Mean change from baseline in retrospective daytime (AM) nasal individual symptom scores (rhinorrhea, nasal congestion, nasal itch, and sneezing) at 2 weeks and 4 weeks of treatment.
Time frame: Baseline up to 2 and 4 weeks
Daily retrospective nasal single symptom score during night
Mean change from baseline in retrospective nasal individual symptom (rhinorrhea, nasal congestion, nasal itch, and sneezing) scores at night (PM) at 2 weeks and 4 weeks of treatment.
Time frame: Baseline up to 2 and 4 weeks
Daily retrospective total score of ocular symptoms
Mean change from baseline in the retrospective Total Ocular Symptom Score (rTOSS) at 2 weeks or 4 weeks of treatment.
Time frame: Baseline up to 2 and 4 weeks
Total score of retrospective ocular symptoms during daytime each day
Mean change from baseline in the total daytime retrospective ocular symptom score (AM rTOSS) at 2 weeks and 4 weeks of treatment.
Time frame: Baseline up to 2 and 4 weeks
Total score of retrospective ocular symptoms each night
The average change in the retrospective total ocular symptom score (PM rTOSS) at night compared to baseline after 2 weeks and 4 weeks of treatment.
Time frame: Baseline up to 2 and 4 weeks
Total score of instantaneous ocular symptoms before medication in the morning every day
Mean change from baseline in instantaneous total ocular symptom score (iTOSS) before medication administration in the morning, at 2 weeks and 4 weeks of treatment.
Time frame: Baseline up to 2 and 4 weeks
Daily retrospective total score of ocular symptoms
Mean percentage change in total retrospective ocular symptom score from baseline at 2 weeks and 4 weeks of treatment, respectively.
Time frame: Baseline up to 2 and 4 weeks
Total score of instantaneous ocular symptoms before medication each morning
Mean percentage change from baseline in total ocular symptom score immediately before medication administration in the morning, for the 2-week and 4-week treatment periods.
Time frame: Baseline up to 2 and 4 weeks
Daily retrospective scoring of individual ocular symptoms
Mean change in individual ocular symptom scores from baseline to 2 weeks and 4 weeks after treatment, retrospectively assessed daily.
Time frame: Baseline up to 2 and 4 weeks
Daily retrospective scoring of individual ocular symptoms during the day
Mean change from baseline in retrospective ocular symptom scores during daytime (AM) on each day at 2 weeks and 4 weeks of treatment.
Time frame: Baseline up to 2 and 4 weeks
Nightly retrospective scoring of individual ocular symptoms
Mean change from baseline in retrospective ocular symptom scores at night (PM) at 2 weeks and 4 weeks of treatment
Time frame: Baseline up to 2 and 4 weeks
Quality of Life Questionnaire Score for Patients with Allergic Rhinitis
The change in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) scores from baseline for patients with allergic rhinitis after 2 weeks and 4 weeks of treatment.
Time frame: Baseline up to 2 and 4 weeks
Daily retrospective total score of nasal symptoms
The area under the curve representing the average change in the retrospective total nasal symptom score (rTNSS) from baseline, calculated for each day during the 2-week and 4-week treatment periods.
Time frame: Baseline up to 2 and 4 weeks
Blood eosinophil count and percentage
Changes in eosinophil count and percentage from baseline, as well as the percentage of change, at each evaluation visit point.
Time frame: Baseline up 12 weeks
Serum total immunoglobulin E concentration
The changes in serum total immunoglobulin E concentration and the percentage of change from baseline at each evaluation visit point.
Time frame: Baseline up 12 weeks
Forced expiratory volume in 1 second (FEV1) before bronchodilator administration (BD) in subjects with concomitant asthma
The change in forced expiratory volume in one second (FEV1) relative to baseline before the use of bronchodilator (BD) in subjects with asthma across all visit points.
Time frame: Baseline up 12 week
Started Mar 2026 (actual). Primary completion is estimated for Nov 2026, 8 months after the start.
Of 24 phase 2 interventional studies under Rhinitis, Allergic, Seasonal, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 23. This study's planned 8 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: TQH2722
Rhinitis, Allergic, Seasonal →
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. →